Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ADMA Biologics's ROE % for the quarter that ended in Mar. 2026 was 41.79%. ADMA Biologics's PB Ratio for the quarter that ended in Mar. 2026 was 5.36.
ADMA Biologics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was 7.80%.
ADMA Biologics ROE % Adjusted to Book Value Related Terms
ADMA Biologics ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for ADMA Biologics's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADMA vs ZLAB, HRMY, STOK: ROE % Adjusted to Book Value Comparison
For the Biotechnology subindustry, ADMA Biologics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ADMA Biologics ROE % Adjusted to Book Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ADMA Biologics's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where ADMA Biologics's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of 7.80% mean?
ADMA Biologics (ADMA) has a ROE % Adjusted to Book Value of 7.80% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on ADMA Biologics and its competitors.
Is ADMA Biologics' ROE % Adjusted to Book Value too high?
ADMA Biologics' current ROE % Adjusted to Book Value is 7.80%. Overall, ADMA Biologics has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ADMA Biologics' ROE % Adjusted to Book Value compare to ZLAB and HRMY?
ADMA Biologics' ROE % Adjusted to Book Value of 7.80% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on ADMA Biologics and its competitors. ADMA Biologics's current ROE % Adjusted to Book Value is 7.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADMA Biologics stock overvalued right now?
Based on GuruFocus' analysis, ADMA Biologics (ADMA) is currently considered Significantly Undervalued. The stock's GF Value™ is $18.10, compared to a current price of $8.68 — trading 52% below its estimated fair value. The current ROE % Adjusted to Book Value is 7.80%. ADMA Biologics' overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For ADMA Biologics (ADMA), the current ROE % Adjusted to Book Value is 7.80% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ADMA Biologics (ADMA) Overvalued in 2026?
Based on GuruFocus' analysis, ADMA Biologics stock appears to be undervalued.
The current stock price of $8.68 is trading 52% below its estimated GF Value™ of $18.10.
GuruFocus considers ADMA Biologics to be Significantly Undervalued.
Key valuation signals for ADMA:
ROE % Adjusted to Book Value: 7.80%
GF Value™: $18.10 vs. price of $8.68 (52% below fair value)
No single metric tells the full story. See the ADMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
64GF Score
Get the complete analysis for ADMA
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADMA has been successfully added to your 
